Description: Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Home Page: www.inventivapharma.com
50 rue de Dijon
Daix,
21121
France
Phone:
33 3 80 44 75 00
Officers
| Name | Title |
|---|---|
| Mr. Frederic Cren | Co-Founder, CEO & Chairman |
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy CEO & Director |
| Mr. Jean Volatier | Deputy GM & CFO |
| Ms. Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer |
| Mr. Eric Duranson L.L.M. | General Counsel |
| Ms. Nathalie Harroy | Head of Human Resources |
| Dr. Kristina Meyer Ph.D. | Executive VP and Business Development & Alliance Management |
| Dr. Michael Cooreman | Chief Medical Officer |
| Ms. Pascaline Clerc Ph.D. | Executive Vice President of Strategy & Corporate Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0183 |
| Price-to-Sales TTM: | 11.0529 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 123 |